The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for evaluation in their pipeline of therapeutic antibodies for advanced cancer.
Dr. Valerie Vanhooren, CEO of ONA Therapeutics, said:
We are delighted to be working with the highly experienced mAbsolve team. Having access to the novel Fc silencing solution represents a significant milestone in our project, creating a safer and more effective therapeutic.
Dr. Ian Wilkinson, CSO of mAbsolve, said:
We are excited to work with the ONA Therapeutics team on a highly innovative project. This is another clear example where alternative Fc silencing options were deemed to represent an unacceptable risk and a superior totally silent option was required. We are delighted to be able to offer this in the form of our STR technology.